Company Encyclopedia
View More
name
Vera Therapeutics
VERA.US
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc.
1.907 T
VERA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NVIDIA (Minutes): Target gross margin for next year is 75%, collaboration with OpenAI is not blind

    The following are the minutes of NVIDIA's FY2026 Q3 earnings call, compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article 'More Important Than Non-Farm Payrolls! Can NVIDIA Save the US Stock Market Again?' Compared to the earnings report, the information conveyed in this earnings call is more critical: ① Data Center Revenue: GB300 sales surpassed GB200, contributing about two-thirds of Blackwell's total revenue. Hopper revenue was approximately $2 billion, with H20 accounting for about $50 million; Regarding guidance: the company provided revenue guidance for the next quarter...

    NA
    OpenAI
    0.00%
    US
    KSA
    +0.24%
    US
    NVDA
    -0.97%
    NA
    OpenAI
    0.00%
    US
    KSA
    +0.24%
    US
    NVDA
    -0.97%

    Vera Therapeutics SVP Finance Joseph R. Young Reports Sale of Common Shares

    Joseph R. Young, SVP, Finance and Chief Accounting Officer of Vera Therapeutics Inc., reported the sale of common shares of the company. The information was published via EDGAR by the U.S. Securities and Exchange Commission on November 13, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    VERA
    +2.12%
    Reuters·
    US
    VERA
    +2.12%

    Vera Therapeutics shares are trading higher after the company announced its ORIGIN Phase 3 trial met its primary endpoint. HC Wainwright maintained a Buy rating on the stock and raised its price target from $85 to $90.

    benzinga_article·
    US
    VERA
    +2.12%
    benzinga_article·
    US
    VERA
    +2.12%

    Vera Therapeutics to Present at TD Cowen Immunology & Inflammation Summit

    Vera Therapeutics Inc., a late clinical-stage biotechnology company, will present at the TD Cowen Immunology & Inflammation Summit on November 13, 2025. The event will be virtual, and the management team will also engage in one-on-one investor meetings. This announcement was originally published via GlobeNewswire on November 10, 2025.

    Reuters·
    US
    VERA
    +2.12%
    Reuters·
    US
    VERA
    +2.12%

    Key facts: JP Morgan cuts Vera Therapeutics price target to $52; company announces inducement grants

    JP Morgan has reduced its price target for Vera Therapeutics from $53.00 to $52.00 per share.1Vera Therapeutics announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4).2

    TradingView·
    US
    VERA
    +2.12%
    TradingView·
    US
    VERA
    +2.12%
    Posts
    View More

    Nvidia CEO Jensen Huang interview with Bloomberg News after 3rd quarter earnings call (Link below). $NVIDIA(NVDA.US) #Semiconductors

    -Question (Q) on Blackwell sales:

    Jensen: “I said, sales are off the...................................................

    $NVIDIA(NVDA.US) - NVIDIA Q3 EARNINGS PREVIEW (NOV 19, 2025)

    Nvidia reports fiscal Q3 results after the close on Wednesday. The print is widely seen as a key test for the sustainability of the AI bull ......................................................

    $AMD(AMD.US)$Oracle(ORCL.US)Oracle will deploy AMD’s MI450 AI chips in the third quarter of 2026, directly targeting Nvidia’s AI chips. The MI450 is said to be AMD’s most advanced GPU (graphics proces...